A randomized clinical trial looking at disabling fatigue in multiple sclerosis occurs frequently. How should it be treated? A randomized clinical trial

Completed (inferred)Not a drug-phase studyEarly (CIS/RIS)ISRCTN69520623

What it found

Paper found, not read

A paper reports the results; we have not read it yet. See Papers below.

What it measured

Main measures

  • 1. Fatigue: checklist individual strength (CIS) subscale fatigue 2. Participation: impact on participation and autonomy (IPA)

    FatiguePhysical function

Other measures (1)

  • 1. Medical outcome study short form 36 (SF36) 2. Rehabilitation activities profile (RAP) 3. Fatigue severity scale (FSS) 4. Checklist individual strength (CIS) subscales motivation, concentration, activity modified fatigue impact scale (MFIS)

    FatiguePhysical functionQuality of life (reported by participants)

Who could take part

Early (CIS/RIS) · 18 to 70

Show the full criteria

Inclusion criteria

Inclusion: 1. Diagnosis of MS according to the criteria of McDonald 2. Able to walk with no more than one unilateral walking aid i.e. able to walk with no more than one unilateral walking aid 3. Suffering from fatigue, defined as a score higher than 35 on the subscale fatigue of the Checklist Individual Strength (CIS) 4. Age between 18-70 years Exclusion: 1. Patients using in the last three months prior to inclusion Amantadine, Modafinil, Ritalin or Pemoline for their fatigue 2. Major depression

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Not provided at time of registration

Papers

Loading reviews and guidelines…

History

    1. Started

      Sept 2011

    2. Finished

      Apr 2014

    Assembled by software from public sources.